logo
login
Login
Services
Services
About master page
About
News
News
Contact
Contact
EN
HerediGENE

HerediGENE

HerediGENE is a test that fully analyzes a panel of genes, including BRCA1 and BRCA2, which are responsible for increased risk of developing breast, ovarian and other hereditary cancers.

Learn more
OncotypeDX<sup>®</sup><br /> Breast

OncotypeDX®
Breast

The OncotypeDX® breast cancer test is a diagnostic test created to help patients who have been recently diagnosed with early stage, estrogen receptor positive breast cancer.

Learn more
Com.Pl.i.t. DX<br/> Assay

Com.Pl.i.t. DX
Assay

Com.Pl.i.t. DX Assay is a multigene test designed to help you and your physician make informed treatment decisions based on the unique biology of your tumor and individualize your treatment.

Learn more
Mo.Re.

Mo.Re.

Mo.Re. (Molecular Response) is a multi-gene assay developed to provide an insight to the tumor’s biology of each patient.

Learn more
cloud
cloud

Services

Molecular Genetics

Genekor is specialized in molecular genetics.

Utilizing cutting edge technology, our company offers all the validated molecular tools for the diagnosis, prognosis and individualized treatment.

cloud
cloud

Services

Oncology, Cardiology, Neurology and Pharmacogenetics

We focus on oncology, cardiology, neurology and pharmacogenomics. Our goal is to achieve the most direct, most valid and most economical diagnostic procedure in order to generally improve patient care.

Company

Genekor

GeneKor is multinational molecular diagnostics company founded in 2007 and operates molecular biology laboratories with state of the art equipment suitable to provide the highest quality of Molecular Services . We provide a diversification of services focused on improving patient care utilizing the latest technologies of prognostic, predictive, and personalized medicine.

The clinical expertise of GeneKor focuses on:

  • Response to Targeted Therapy
  • Pharmacogenetics
  • Determination of Hereditary Cancer (Breast Cancer , Colon Cancer , Thyroid Cancer , Pancreatic Cancer , etc.)
  • New Unique Technological Platforms (OncotypeDX BreastTM, OncotypeDX ColonTM, OncotypeDX ProstateTM, PCA3TM)

Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing

KONSTANTINOS AGIANNITOPOULOS1, GEORGIA PEPE1, GEORGIOS N. TSAOUSIS1, KEVISA POTSKA1, DIMITRA BOUZARELOU1, ANASTASIA KATSELI 1, CHRISTINA NTOGKA1, ANGELIKI MEINTANI 1, NIKOLAOS TSOULOS1, STYLIANOS GIASSAS2, VASSILEIOS VENIZELOS3, CHRISTOS MARKOPOULOS4, RODONIKI IOSIFIDOU5, SOFIA KARAGEORGOPOULOU2, CHRISTOS CHRISTODOULOU3, IOANNIS NATSIOPOULOS6, KONSTANTINOS PAPAZISIS7, MARIA VASILAKI-ANTONATOU8, ELEFTHERIOS KABLETSAS9, AMANTA PSYRRI 10, DIMITRIOS ZIOGAS11, EFTHALIA LALLA4, ANNA KOUMARIANOU10, KORNILIA ANASTASAKOU3, CHRISTOS PAPADIMITRIOU12, VAHIT OZMEN13, SUALP TANSAN14, KERIM KABAN15, TAHSIN OZATLI 16, DAN TUDOR ENIU17, ANGELICA CHIOREAN18, ALEXANDRU BLIDARU19, MARRIT RINSMA20, EIRINI PAPADOPOULOU1 and GEORGE NASIOULAS1

K. Agiannitopoulos et al 2023

Application of next generation sequencing in cardiology: current and future precision medicine implications

Eirini Papadopoulou1 *, Dimitra Bouzarelou1 , George Tsaousis1 , Athanasios Papathanasiou1 , Georgia Vogiatzi2 , Charalambos Vlachopoulos3 , Antigoni Miliou3 , Panagiota Papachristou4 , Efstathia Prappa5 , Georgios Servos6 , Konstantinos Ritsatos7 , Aristeidis Seretis7 , Alexandra Frogoudaki8 and George Nasioulas1

Eirini Papadopoulou et al 2023

Genetic Predisposition to Male Breast Cancer: A Case Series

Angela Apessos, Konstantinos Agiannitopoulos, Georgia Pepe, Georgios N. Tsaousis, Panagiota Pitta, Chrysanthi Bili, Lina Florentin, Emmanouel Saloustros, Eleftherios Kampletsas, Dimitrios Tryfonopoulos, Nikolaos Tsoukalas, Evangelos Bournakis, Flora Zagouri, Athanassios Kotsakis, Anna Koumarianou, Ippokratis Korantzis, Ioannis Boukovinas, George Lypas, Georgios Fountzilas, Vasiliki Michalaki, Spyridon Xynogalos, Helena Linardou, Eirini Papadopoulou, George Nasioulas and Vassilis Georgoulias

Angela Apessos et al 2022
Change cookies consent Revoke cookies consent